Burjeel Holdings Accelerates Strategic Execution in Q2 2025 with Expanded Specialized Services, Infrastructure Ownership, and Innovation-Driven Growth
Burjeel Holdings, a leading integrated healthcare services provider in the MENA region, reported a robust second quarter in 2025, marked by accelerated execution of its multi-pronged strategy focused on specialization, operational efficiency, and regional expansion. The Group made significant advances in oncology, mental health, physiotherapy, primary care, and medical innovation, underscoring its ambition to lead in high-growth, high-impact healthcare domains while strengthening its long-term operating model.
Reinforcing Leadership in Oncology Through Strategic Network Expansion
A key highlight of Q2 2025 was Burjeel’s expansion of its advanced oncology platform, which remains one of the Group’s core areas of expertise and investment. Building on its reputation as a regional leader in complex cancer care, Burjeel deepened its footprint in the oncology sector by integrating the Advanced Care Oncology Center in Dubai into its network. This high-acuity facility brings additional capacity and talent into Burjeel’s oncology ecosystem, creating synergies that enhance access and elevate standards of cancer treatment across the UAE.
In parallel, the Group opened new Burjeel Cancer Institute (BCI) clinics in Al Ain, Sharjah, and Oman—an ambitious multi-site expansion aimed at bringing high-quality cancer services closer to patients in underserved areas. This geographical diversification strengthens Burjeel’s position as a cross-border oncology provider, with a growing network capable of managing a wide spectrum of cancer types across stages of care.
Further bolstering its capabilities, Burjeel inaugurated the UAE’s first dedicated cancer pharmacy during the quarter. This specialized unit plays a critical role in enhancing pharmaceutical support for oncology patients, ensuring timely access to life-saving medications, personalized dosing, and better compliance management. The initiative reflects Burjeel’s comprehensive approach to cancer care, spanning diagnostics, treatment, medication, and follow-up.
Scaling Mental Health Services Through Alkalma JV
Recognizing the rising demand for mental health services across the region, Burjeel made a major strategic move by scaling up its mental wellness operations through Alkalma, its dedicated joint venture in the mental health space. In Q2 2025, the Group launched four specialist mental health centers—two in the UAE and two in Saudi Arabia—under the Alkalma brand. These centers offer multidisciplinary psychiatric and psychological services, including adult and pediatric mental health care, counseling, addiction treatment, and neurodevelopmental therapy.
This initial rollout represents the first phase of a multi-year expansion roadmap for Alkalma, which aims to create a regionally integrated mental health platform capable of addressing stigma, access, and treatment gaps across the Gulf. By entering this historically underserved sector at scale, Burjeel is positioning itself as a first mover in what is expected to be a high-growth healthcare vertical over the coming decade.
Expansion into Saudi Arabia Through Targeted Physiotherapy Acquisition
As part of its continued push into the Kingdom of Saudi Arabia (KSA), Burjeel acquired a major physiotherapy facility in Riyadh, expanding its PhysioTherabia platform. This acquisition provides both operational scale and strategic leverage, as the facility holds long-term government contracts that unlock revenue certainty and institutional access.
The move aligns with Burjeel’s broader KSA market entry and growth strategy, focused on high-impact, high-demand specialties where the Group can replicate its UAE success. Moreover, the acquisition offers substantial turnaround potential, as Burjeel intends to apply its proven operational excellence to enhance service delivery, patient outcomes, and financial performance at the newly integrated facility.
Strengthening Operational Resilience Through Real Estate Ownership
Another major development in Q2 2025 was the Group’s acquisition of the Medeor Hospital Dubai building for AED 170 million. This strategic real estate transaction marks a key milestone in Burjeel’s efforts to optimize its capital structure and reduce long-term liabilities. By converting lease obligations into asset ownership, the Group gains greater flexibility in managing costs, future-proofing its operations, and increasing enterprise value.
Ownership of the facility also enhances Burjeel’s ability to invest in upgrading the site to meet future demand trends, such as introducing new specialties, scaling high-margin services, or expanding inpatient capacity.
Growing the Primary Care Footprint in Urban Growth Corridors
Continuing its mission to improve access to primary and preventive care, Burjeel launched a new medical center on Saadiyat Island during the quarter. Strategically located in a fast-growing urban district with a high-density, high-income population, the new facility aligns with Burjeel’s plan to establish a broad-based outpatient care ecosystem that feeds into its larger hospitals and specialty centers.
This new center expands the Group’s primary care network in Abu Dhabi, further strengthening its ability to offer integrated care pathways—from general medicine to specialist referrals—under a single coordinated platform.
Pioneering Innovation Through Strategic Partnerships and Research
Innovation remained a central pillar of Burjeel’s Q2 2025 performance, with several pioneering projects launched during the period. Notably, the Group unveiled DOCKTOUR, a healthcare logistics joint venture with AD Ports Group. This initiative is designed to revolutionize the delivery of medical services and infrastructure to remote and underserved populations by leveraging the logistics and port infrastructure expertise of AD Ports with Burjeel’s clinical capabilities.
DOCKTOUR is expected to deliver mobile clinics, modular hospitals, and health screening units to islands, labor camps, and rural areas, where access to healthcare has historically been limited. This transformative model not only addresses access barriers but also opens new markets and revenue streams for Burjeel.
In clinical innovation, Burjeel opened the region’s first Al Muderis Osseointegration Clinic, offering advanced solutions for limb reconstruction, including prosthetic implants for amputees. The Group also expanded its capabilities in managing neurological and metabolic disorders, with the launch of a state-of-the-art Epilepsy Monitoring Unit and new programs focused on rare diseases, hematology, and metabolic syndromes.
Advancing AI-Powered Diagnostics and Space Health Research
On the digital front, Burjeel made notable strides in its ongoing digital transformation. The Group has integrated AI-powered diagnostic tools across select specialties, streamlining radiology workflows, improving early detection, and enhancing diagnostic accuracy. These solutions are also improving patient throughput and clinical decision-making across Burjeel facilities.
One of the most futuristic aspects of Burjeel’s Q2 innovation drive was its involvement in space medicine research, particularly studying the impact of microgravity on diabetes and metabolic diseases. These studies aim to translate space-based insights into practical innovations for managing chronic diseases on Earth, reinforcing Burjeel’s commitment to leading-edge translational research.
